JP7211982B2 - Ｐｒｍｔ５媒介性障害の治療又は予防に有用な化合物 - Google Patents
Ｐｒｍｔ５媒介性障害の治療又は予防に有用な化合物 Download PDFInfo
- Publication number
- JP7211982B2 JP7211982B2 JP2019571788A JP2019571788A JP7211982B2 JP 7211982 B2 JP7211982 B2 JP 7211982B2 JP 2019571788 A JP2019571788 A JP 2019571788A JP 2019571788 A JP2019571788 A JP 2019571788A JP 7211982 B2 JP7211982 B2 JP 7211982B2
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- hydrate
- alkyl
- salt
- membered heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704327.4A GB201704327D0 (en) | 2017-03-17 | 2017-03-17 | Compounds |
| GB1704327.4 | 2017-03-17 | ||
| PCT/EP2018/056663 WO2018167269A1 (en) | 2017-03-17 | 2018-03-16 | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510091A JP2020510091A (ja) | 2020-04-02 |
| JP2020510091A5 JP2020510091A5 (enExample) | 2021-04-30 |
| JP7211982B2 true JP7211982B2 (ja) | 2023-01-24 |
Family
ID=58688233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571788A Active JP7211982B2 (ja) | 2017-03-17 | 2018-03-16 | Ｐｒｍｔ５媒介性障害の治療又は予防に有用な化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11485731B2 (enExample) |
| EP (1) | EP3596061B1 (enExample) |
| JP (1) | JP7211982B2 (enExample) |
| KR (1) | KR102616970B1 (enExample) |
| CN (1) | CN110650950B (enExample) |
| AU (2) | AU2018235139A1 (enExample) |
| CA (1) | CA3056724A1 (enExample) |
| GB (1) | GB201704327D0 (enExample) |
| IL (1) | IL269354B2 (enExample) |
| MX (1) | MX2019011061A (enExample) |
| NZ (1) | NZ757500A (enExample) |
| SG (1) | SG11201908598PA (enExample) |
| WO (1) | WO2018167269A1 (enExample) |
| ZA (1) | ZA201906269B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| US11464783B2 (en) | 2019-06-06 | 2022-10-11 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
| CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
| ES3074517T3 (en) | 2019-12-17 | 2026-07-21 | Merck Sharp & Dohme Llc | 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease |
| EP4076459B1 (en) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| AU2021283568B2 (en) * | 2020-06-02 | 2023-12-14 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | 3,4-dihydroisoquinoline compound and use thereof |
| BR112022025037A2 (pt) | 2020-06-10 | 2023-02-14 | Aligos Therapeutics Inc | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus |
| CN115768769B (zh) * | 2020-06-30 | 2024-10-22 | 南京再明医药有限公司 | 四氢异喹啉类化合物及其用途 |
| KR102920599B1 (ko) | 2020-09-04 | 2026-01-29 | 이노웨이스톤 테라퓨틱스 리미티드 | 항종양 활성을 갖는 화합물 및 이의 용도 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Ｔｙｋ２抑制劑及其用途 |
| CA3222626A1 (en) | 2021-05-13 | 2022-11-17 | Yunlong Song | Compound having anti-tumor activity and use thereof |
| GB202108383D0 (en) * | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| AU2022404488B2 (en) * | 2021-12-08 | 2026-04-02 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Salt of 3,4-dihydroisoquinoline compound and use thereof |
| WO2023125947A1 (zh) * | 2021-12-30 | 2023-07-06 | 江苏先声药业有限公司 | 四氢异喹啉类化合物的可药用盐、晶型及其用途 |
| WO2023131305A1 (zh) * | 2022-01-06 | 2023-07-13 | 江苏先声药业有限公司 | Prmt5抑制剂和抗癌治疗剂的组合 |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016505596A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| WO2015200680A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160466A4 (en) * | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US10494376B2 (en) | 2014-09-03 | 2019-12-03 | Ctxt Pty. Ltd. | Tetrahydroisoquinoline derived PRMT5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
-
2017
- 2017-03-17 GB GBGB1704327.4A patent/GB201704327D0/en not_active Ceased
-
2018
- 2018-03-16 CA CA3056724A patent/CA3056724A1/en active Pending
- 2018-03-16 AU AU2018235139A patent/AU2018235139A1/en not_active Abandoned
- 2018-03-16 EP EP18714178.3A patent/EP3596061B1/en active Active
- 2018-03-16 KR KR1020197030311A patent/KR102616970B1/ko active Active
- 2018-03-16 CN CN201880032332.4A patent/CN110650950B/zh active Active
- 2018-03-16 SG SG11201908598P patent/SG11201908598PA/en unknown
- 2018-03-16 NZ NZ757500A patent/NZ757500A/en unknown
- 2018-03-16 IL IL269354A patent/IL269354B2/en unknown
- 2018-03-16 JP JP2019571788A patent/JP7211982B2/ja active Active
- 2018-03-16 WO PCT/EP2018/056663 patent/WO2018167269A1/en not_active Ceased
- 2018-03-16 US US16/494,532 patent/US11485731B2/en active Active
- 2018-03-16 MX MX2019011061A patent/MX2019011061A/es unknown
-
2019
- 2019-09-23 ZA ZA2019/06269A patent/ZA201906269B/en unknown
-
2022
- 2022-04-11 AU AU2022202389A patent/AU2022202389B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016505596A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
Non-Patent Citations (1)
| Title |
|---|
| REGISTRY（STN）［online］，2017年02月20日，2072502-51-1他多数 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL269354B1 (en) | 2023-07-01 |
| EP3596061C0 (en) | 2023-09-06 |
| NZ757500A (en) | 2026-03-27 |
| MX2019011061A (es) | 2019-12-19 |
| AU2018235139A1 (en) | 2019-10-17 |
| EP3596061A1 (en) | 2020-01-22 |
| KR20190129936A (ko) | 2019-11-20 |
| US20200325128A1 (en) | 2020-10-15 |
| GB201704327D0 (en) | 2017-05-03 |
| IL269354A (en) | 2019-11-28 |
| KR102616970B1 (ko) | 2023-12-22 |
| CN110650950B (zh) | 2023-09-19 |
| BR112019019358A2 (pt) | 2020-04-14 |
| CN110650950A (zh) | 2020-01-03 |
| CA3056724A1 (en) | 2018-09-20 |
| AU2022202389A1 (en) | 2022-05-05 |
| AU2022202389B2 (en) | 2024-04-18 |
| WO2018167269A1 (en) | 2018-09-20 |
| JP2020510091A (ja) | 2020-04-02 |
| ZA201906269B (en) | 2024-03-27 |
| US11485731B2 (en) | 2022-11-01 |
| SG11201908598PA (en) | 2019-10-30 |
| EP3596061B1 (en) | 2023-09-06 |
| IL269354B2 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102616970B1 (ko) | Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물 | |
| JP7308765B2 (ja) | 増殖性障害の治療に使用される三環式化合物 | |
| ES2975661T3 (es) | Inhibidores de BCL6 derivados de la 2-quinolona | |
| KR20250153866A (ko) | Dna 중합효소 세타 억제제 | |
| AU2022229939A1 (en) | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | |
| US20230045929A1 (en) | Isoquinoline derivatives as sik2 inhibitors | |
| WO2025262192A1 (en) | Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors | |
| WO2021084265A1 (en) | Isoquinoline derivatives as sik2 inhibitors | |
| AU2022290645A1 (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| WO2023094834A1 (en) | Isoindolines as pms2 inhibitors | |
| BR112019019358B1 (pt) | Compostos, composição farmacêutica, uso dos referidos compostos, método in vitro para alterar a expressão gênica em uma célula e combinação compreendendo um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210315 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210315 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220314 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220908 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230112 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7211982 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |